Version 1
: Received: 11 July 2024 / Approved: 11 July 2024 / Online: 12 July 2024 (04:23:46 CEST)
How to cite:
Martínez-Razo, G.; Pires, P. C.; Avilez-Colin, A.; Domínguez-López, M. L.; Veiga, F.; Conde-Vazquéz, E.; Paiva-Santos, A. C.; Vega-López, A. Evaluation of a Norcantharidin Nanoemulsion Efficacy for Treating B16F1-Induced Melanoma in a Syngeneic Murine Model. Preprints2024, 2024070960. https://doi.org/10.20944/preprints202407.0960.v1
Martínez-Razo, G.; Pires, P. C.; Avilez-Colin, A.; Domínguez-López, M. L.; Veiga, F.; Conde-Vazquéz, E.; Paiva-Santos, A. C.; Vega-López, A. Evaluation of a Norcantharidin Nanoemulsion Efficacy for Treating B16F1-Induced Melanoma in a Syngeneic Murine Model. Preprints 2024, 2024070960. https://doi.org/10.20944/preprints202407.0960.v1
Martínez-Razo, G.; Pires, P. C.; Avilez-Colin, A.; Domínguez-López, M. L.; Veiga, F.; Conde-Vazquéz, E.; Paiva-Santos, A. C.; Vega-López, A. Evaluation of a Norcantharidin Nanoemulsion Efficacy for Treating B16F1-Induced Melanoma in a Syngeneic Murine Model. Preprints2024, 2024070960. https://doi.org/10.20944/preprints202407.0960.v1
APA Style
Martínez-Razo, G., Pires, P. C., Avilez-Colin, A., Domínguez-López, M. L., Veiga, F., Conde-Vazquéz, E., Paiva-Santos, A. C., & Vega-López, A. (2024). Evaluation of a Norcantharidin Nanoemulsion Efficacy for Treating B16F1-Induced Melanoma in a Syngeneic Murine Model. Preprints. https://doi.org/10.20944/preprints202407.0960.v1
Chicago/Turabian Style
Martínez-Razo, G., Ana Cláudia Paiva-Santos and Armando Vega-López. 2024 "Evaluation of a Norcantharidin Nanoemulsion Efficacy for Treating B16F1-Induced Melanoma in a Syngeneic Murine Model" Preprints. https://doi.org/10.20944/preprints202407.0960.v1
Abstract
Melanoma, one of the most aggressive forms of skin cancer, is also one of the most diagnosed cancer types. While surgical excision of the lesions is the primary treatment for melanoma, not all cases are candidates for surgical procedures. New treatments and complementary options are necessary, given the increasing diagnosis rate. In the present study, a norcantharidin-containing nanoemulsion was developed and evaluated in vivo using a syngeneic graft murine model. Our model contemplates an amputation surgery simulating the standard treatment and the role of the nanoemulsion as a potential adjuvant therapy. We observed a significant decrease in the growth rate of the melanoma lesion in the treated groups compared to the control group, both at the 20th and 30th days of treatment. Moreover, we evaluated the drug bioavailability in serum samples, and the results showed that norcantharidin was detectable in a range of 0.1 to 0.18 mg per mL in the treated groups. Furthermore, histopathological analysis was performed on the amputated tumors, where significant differences were found regarding size, mitosis rate, lymphocytic infiltration, and multispectral quantitative image analysis compared to the control group. The norcantharidin-containing nanoemulsion could be a potential alternative or adjuvant therapy if more clinical studies are conducted. Topical nanosystems can become or complement standard therapies, which is needed as melanoma affects not only in terms of mortality but also the patient's morbidity and life quality.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
